Mouse anti-Human/Mouse/Rat sapiens (Human) NRAS Monoclonal Antibody

Function

Signal transducer in the Ras-MAPK signaling pathway that regulates cell proliferation and survival (PubMed:30712867). Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:30712867). Recognized by LZTR1 that mediates its ubiquitination by a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex (PubMed:40934300)

Subcellular Location

Cell membrane (Lipid-anchor); Golgi apparatus membrane (Lipid-anchor)

Disease Association

Leukemia, juvenile myelomonocytic (JMML) : An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. [The disease is caused by variants affecting the gene represented in this entry] | Noonan syndrome 6 (NS6) : A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. [The disease is caused by variants affecting the gene represented in this entry] | RAS-associated autoimmune leukoproliferative disorder (RALD) : A disorder of apoptosis, characterized by chronic accumulation of non-malignant lymphocytes, defective lymphocyte apoptosis, and an increased risk for the development of hematologic malignancies. [The disease is caused by variants affecting the gene represented in this entry] | Melanocytic nevus syndrome, congenital (CMNS) : A syndrome characterized by congenital pigmentary skin lesions which can occur at any site and can cover most of the body surface. These lesions may or may not be hairy. Congenital melanocytic nevi are associated with neuromelanosis (the presence of melanin-producing cells within the brain parenchyma or leptomeninges). Less commonly they are associated with malignant melanoma in childhood, both in the skin and the central nervous system. CMNS patients also tend to have a characteristic facial appearance, including wide or prominent forehead, periorbital fullness, small short nose with narrow nasal bridge, round face, full cheeks, prominent premaxilla, and everted lower lip. [The disease is caused by variants affecting the gene represented in this entry] | Melanosis, neurocutaneous (NCMS) : A rare congenital disease characterized by the presence of giant or multiple melanocytic nevi on the skin, foci of melanin-producing cells within the brain parenchyma, and infiltration of leptomeninges by abnormal melanin deposits. Neurologic abnormalities include seizures, hydrocephalus, arachnoid cysts, tumors, and syringomyelia. Some patients may develop malignant melanoma. [The disease is caused by variants affecting the gene represented in this entry] | Keratinocytic non-epidermolytic nevus (KNEN) : Epidermal nevi of the common, non-organoid and non-epidermolytic type are benign skin lesions and may vary in their extent from a single (usually linear) lesion to widespread and systematized involvement. They may be present at birth or develop early during childhood. [The disease is caused by variants affecting the gene represented in this entry] | Thyroid cancer, non-medullary, 2 (NMTC2) : A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms. [Disease susceptibility is associated with variants affecting the gene represented in this entry]

Subunit

Interacts (active GTP-bound form preferentially) with RGS14 (By similarity). Interacts (active GTP-bound form) with RASSF7 (PubMed:21278800). Interacts (active GTP-bound form) with both SHOC2 and PP1c (all isoforms) to form a tertiary complex; SHOC2 and PP1c preferably bind M-Ras/MRAS, but they also bind K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS (PubMed:36175670, PubMed:35768504, PubMed:35831509, PubMed:35830882). Interacts (GDP-bound form) with LZTR1; this interaction mediates NRAS ubiquitination by BCR E3 ligase complex (PubMed:40934300)

• Taparowsky E. et al. Structure and activation of the human N-ras gene. — Cell (1983)
• Hall A. et al. Human N-ras: cDNA cloning and gene structure. — Nucleic Acids Res. (1985)
• Brown R. et al. Mechanism of activation of an N-ras gene in the human fibrosarcoma cell line HT1080. — EMBO J. (1984)
• Yuasa Y. et al. Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells. — Proc. Natl. Acad. Sci. U.S.A. (1984)
• Puhl H.L. III et al. cDNA clones of human proteins involved in signal transduction sequenced by the Guthrie cDNA resource center (www.cdna.org). (MAR-)
• PubMed: CI-9GALKN8DBTP2G (OCT-)
• The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). — Genome Res. (2004)
• Hirai H. et al. Transforming genes in human leukemia cells. — Blood (1985)